Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 929 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Stereotactic radiotherapy Clear all

Conditions: Metastatic Prostate Cancer
Interventions: Atezolizumab, Abiraterone, Prednisone, GnRH analog, Stereotactic Body Radiotherapy (SBRT), Enzalutamide, Follow up; Drug · Radiation · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions: stereotactic body radiation therapy, therapeutic conventional surgery, laboratory biomarker analysis; Radiation · Procedure · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Leydig Cell Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Pseudomyxoma Peritonei, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer, Recurrent Uterine Sarcoma, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer
Interventions: stereotactic body radiation therapy, carboplatin, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacogenomic studies; Radiation · Drug · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 19 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Small Bowel Cancer, Colorectal Cancer, Appendiceal Cancer, Biliary Cancer, Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Oligoprogressive
Interventions: Ablative local therapy; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2039
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Adverse Radiation Effects, Radiation Necrosis
Interventions: Not listed
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Adenocarcinoma of the Prostate, Stage III Prostate Cancer
Interventions: stereotactic body radiation therapy, quality-of-life assessment, laboratory biomarker analysis, androgen deprivation therapy; Radiation · Other · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lung Cancer
Interventions: Erlotinib, SBRT; Drug · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 2
States / cities: Aurora, Colorado • Dallas, Texas

Conditions: Brain Metastases, Adult
Interventions: Stereotactic radiosurgery; Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Stage II Prostate Adenocarcinoma, Stage IIB Prostate Cancer, Stage III Prostate Adenocarcinoma
Interventions: Laboratory Biomarker Analysis, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy; Other · Radiation
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions: hypofractionated radiation therapy, laboratory biomarker analysis, image-guided radiation therapy, carboplatin, paclitaxel, stereotactic body radiation therapy; Radiation · Other · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Cancer
Interventions: Prostate SBRT with concurrent boost to intraprostatic lesion(s); Radiation
Lead sponsor: Rocky Mountain Cancer Centers; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 2
States / cities: Aurora, Colorado • Littleton, Colorado

Conditions: Brain Cancer, Recurrent Malignant Gliomas, Primary Brain Tumor
Interventions: bevacizumab and radiation (IMRT); Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 2
States / cities: Commack, New York • New York, New York

Conditions: Prostate Cancer, Prostatic Neoplasm
Interventions: 18F-DCFPyL, Tumor Irradiation, Prostate + tumor irradiation; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions: High-Dose Rate Brachytherapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy; Radiation · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: SBRT, Borderline Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer
Interventions: Drug GC4711, Placebo; Drug
Lead sponsor: Galera Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 21
States / cities: Gilbert, Arizona • Los Angeles, California • Miami, Florida + 18 more

Conditions: Brain Metastases
Interventions: Stereotactic Radiosurgery; Radiation
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Brain Tumor - Metastatic
Interventions: Carmustine 7.7Mg Wafer; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 2
States / cities: Detroit, Michigan • Omaha, Nebraska

Conditions: Pancreatic Cancer
Interventions: Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: University of Cincinnati; Other
Eligibility: 19 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
Interventions: Atezolizumab, Biospecimen Collection, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy; Drug · Procedure · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 390
States / cities: Anchorage, Alaska • Jonesboro, Arkansas • Little Rock, Arkansas + 290 more

Conditions: Radiation Necrosis
Interventions: 25% Mannitol, Low-dose Intra-arterial Bevacizumab; Drug
Lead sponsor: Norton Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Lexington, Kentucky • Louisville, Kentucky

Conditions: Prostate Cancer
Interventions: Ultra-hypofractionated radiation therapy, Moderately Hypo-fractionated Radiation Therapy; Radiation
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Head and Neck Cancer
Interventions: Docetaxel, Stereotactic Radiation; Drug · Radiation
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma
Interventions: Standard of Care, SBRT; Other · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 5
States / cities: San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 1 more

Conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Subependymal Giant Cell Astrocytoma, Recurrent Adult Brain Tumor
Interventions: Hyperfractionated radiation therapy, Stereotactic radiosurgery, Alisertib, Quality-of-life assessment; Radiation · Drug · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery

Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer

Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)

Microbiome Determinants of Adverse Effects of Stereotactic Radiosurgery

Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer

Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

SIMT Stereotactic Radiosurgery Outcomes Study

Hypofractionated Stereotactic Body Radiation Therapy for Patients With Prostate Cancer That Was Removed by Surgery

Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Stereotactic Body Radiotherapy (SBRT) With Concurrent Boost for Low- and Intermediate-Risk Prostate Cancer

Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma

Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy

Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer

Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

Stereotactic Radiosurgery Dose Escalation for Brain Metastases

A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease

Neoadjuvant Stereotactic Body Radiation Therapy for Resectable Adenocarcinoma of the Pancreatic Head and/or Body

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)

Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])

Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck

Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial

Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas